Brain magnetic resonance spectroscopy to differentiate recurrent neoplasm from radiation necrosis: A systematic review and meta-analysis.
Humans
Male
Female
Child, Preschool
Child
Adolescent
Young Adult
Adult
Middle Aged
Aged
Neoplasm Recurrence, Local
/ pathology
Diagnosis, Differential
Aspartic Acid
Brain Neoplasms
/ pathology
Magnetic Resonance Spectroscopy
/ methods
Creatine
Radiation Injuries
/ pathology
Choline
Necrosis
/ pathology
Brain
/ pathology
MR spectroscopy
meta-analysis
radiation induced necrosis
recurrent brain tumor
systematic review
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
21
12
2022
received:
23
10
2022
accepted:
21
12
2022
pubmed:
12
1
2023
medline:
15
3
2023
entrez:
11
1
2023
Statut:
ppublish
Résumé
Postradiation treatment necrosis is one of the most serious late sequelae and appears within 6 months. The magnetic resonance spectroscopy imaging (MRSI) has been used for the detection of brain tumors. The study aimed to determine the radiological accuracy and efficacy in distinguishing recurrent brain tumor from radiation-induced necrosis by identifying pseudoprogression. The research was performed in accordance with the preferred reporting items for systematic review and meta-analysis guidelines. International electronic databases including 15 English sources were investigated. A total of 4281 papers with 2159 citations from 15 databases from 2011 to 2021 met the search strategies of magnetic resonance (MR) spectroscopy in recurrent brain tumors and postradiation necrosis. Nine studies were enrolled in the meta-analysis with a total of 354 patients (203 male and 151 female) whose average age ranged from 4 to 74 years. Anbarloui et al., Elias et al., Nemattalla et al., Smith et al., Zeng et al., and Weybright et al. showed strong evidence of heterogeneity regarding choline/N-acetylaspartate (Cho/NAA) ratio in the evaluation of the nine studies. Elias et al., Nemattalla et al., Bobek-Billewicz et al., and Smith et al. showed a high heterogeneity in Cho/creatine (Cr) ratio. Elias et al., Nemattalla et al., Smith et al., and Weybright et al. revealed high heterogeneity in NAA/Cr ratio estimates. MR spectroscopy is effective in distinguishing recurrent brain tumors from necrosis. Our meta-analysis revealed that Cho/NAA, Cho/Cr, and NAA/Cr ratios were significantly better predictor of detected recurrent tumor. Therefore, the MRSI is an informative tool in the distinction of tumor recurrence versus necrosis.
Sections du résumé
BACKGROUND AND PURPOSE
Postradiation treatment necrosis is one of the most serious late sequelae and appears within 6 months. The magnetic resonance spectroscopy imaging (MRSI) has been used for the detection of brain tumors. The study aimed to determine the radiological accuracy and efficacy in distinguishing recurrent brain tumor from radiation-induced necrosis by identifying pseudoprogression.
METHODS
The research was performed in accordance with the preferred reporting items for systematic review and meta-analysis guidelines. International electronic databases including 15 English sources were investigated. A total of 4281 papers with 2159 citations from 15 databases from 2011 to 2021 met the search strategies of magnetic resonance (MR) spectroscopy in recurrent brain tumors and postradiation necrosis.
RESULTS
Nine studies were enrolled in the meta-analysis with a total of 354 patients (203 male and 151 female) whose average age ranged from 4 to 74 years. Anbarloui et al., Elias et al., Nemattalla et al., Smith et al., Zeng et al., and Weybright et al. showed strong evidence of heterogeneity regarding choline/N-acetylaspartate (Cho/NAA) ratio in the evaluation of the nine studies. Elias et al., Nemattalla et al., Bobek-Billewicz et al., and Smith et al. showed a high heterogeneity in Cho/creatine (Cr) ratio. Elias et al., Nemattalla et al., Smith et al., and Weybright et al. revealed high heterogeneity in NAA/Cr ratio estimates.
CONCLUSION
MR spectroscopy is effective in distinguishing recurrent brain tumors from necrosis. Our meta-analysis revealed that Cho/NAA, Cho/Cr, and NAA/Cr ratios were significantly better predictor of detected recurrent tumor. Therefore, the MRSI is an informative tool in the distinction of tumor recurrence versus necrosis.
Substances chimiques
Aspartic Acid
30KYC7MIAI
Creatine
MU72812GK0
Choline
N91BDP6H0X
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
189-201Informations de copyright
© 2023 American Society of Neuroimaging.
Références
Mehta MP, Kotecha RR. CNS tumors: overview. In: Tepper JE, Foote RL, Michalski JM, editors. Gunderson and Tepper's clinical radiation oncology. Netherlands: Elsevier; 2015:479-86.
Brown PD, Chan MD, Shaw EG, et al. Low-grade gliomas. In: Tepper JE, Foote RL, Michalski JM, editors. Gunderson and Tepper's clinical radiation oncology. Netherlands: Elsevier, Inc., 2015:461-5.
Gunjur A, Lau E, Taouk Y, et al. Early post-treatment pseudo progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. J Med Imaging Radiat Oncol. 2011;55:603-10.
Forsyth PA, Kelly PJ, Cascino TI. Radiation necrosis or glioma recurrence: is computer assisted stereotactic biopsy useful? J Neurosurg. 1995;82:436-44.
Gondi V, Vogelbaum MA, Grimm S, et al. Primary intracranial neoplasms. In: Halperin EC, Wazer DE, Perez CA, et al., editors. Perez & Brady's principles and practice of radiation oncology. 7th ed. Philadelphia: Wolter Kluwer; 2019:799-837.
Cammer W. Effects of TNF alpha on immature and mature oligodendrocytes and their progenitors in vitro. Brain Res. 2000;864:213-9.
Chow BM, Li’ YQ, Wong CS. Radiation-induced apoptosis in the adult central nervous system is p53-dependent. Cell Death Differ. 2000;7:712-20.
de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535-7.
Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-3.
Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudo progression after concomitant radio chemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 2008;10:361-7.
Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemo irradiation with temozolomide. Cancer. 2008;113:405-10.
Roldan GB, Scott JN, McIntyre JB, et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci. 2009;36:617-22.
Chaskis C, Neyns B, Michotte A, et al. Pseudoprogression after radiotherapy with concurrent Temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. 2009;72;423-8.
Sanghera P, Perry J, Sahgal A, et al. Pseudo progression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci. 2010;37:36-42.
Young RJ, Gupta A, Shah AD, et al. Potential utility of conventional MRI signs in diagnosing pseudo progression in glioblastoma. Neurology. 2011;76:1918-24.
Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9:453-61.
Mikkelsen T, Snyder J, Hearshen D. Magnetic resonance spectroscopy. In: Newton HB, editor. Handbook of neuro-oncology neuroimaging. New York: Elsevier Ltd.; 2016:327-32.
Croteau D, Scarpace L, Hearshen D, et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery. 2001;49:823-9.
Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery. 2004;54:1111-7.
Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol. 2001;22:604-12.
Kalpathy-Cramer J, Gerstner ER, Emblem KE, et al. Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res. 2014;74:4622-37.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Available from: https://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf. Accessed 11 Feb 2021.
Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol. 2005;185:1471-6.
Zeng QS, Li CF, Liu H, et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys. 2007;68:151-8.
Smith EA, Carlos RC, Junck LR, et al. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol. 2009;192:W45-52.
Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, et al. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol. 2010;48:81-92.
Elias AE, Carlos RC, Smith EA, et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol. 2011;18:1101-8.
Nemattalla WM, El Kady LM, Khalil TH, et al. Differentiation between recurrent glioma and radiation injury by magnetic resonance spectroscopy combined with diffusion-weighted imaging. Suez Canal Univ Med J. 2011;14:45-54.
Anbarloui MR, Ghodsi SM, Khoshnevisan A, et al. Accuracy of magnetic resonance spectroscopy in distinction between radiation necrosis and recurrence of brain tumors. Iran J Neurol. 2015; 14:29-34.
Wang YL, Chen S, Xiao HF, et al. Differentiation between radiation-induced brain injury and glioma recurrence using 3D pCASL and dynamic susceptibility contrast-enhanced perfusion-weighted imaging. Radiother Oncol. 2018;129:68-74.
Zhang Q, Cao J, Zhang J, et al. Differentiation of recurrence from radiation necrosis in gliomas based on the radiomics of combinational features and multimodality MRI images. Comput Math Methods Med. 2019;2019:2893043.
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114:97-109.
Zhang H, Ma L, Wang Q, et al. Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis. Eur J Radiol. 2014;83:2181-9.
Chuang MT, Liu YS, Tsai YS, et al. Differentiating radiation-induced necrosis from recurrent brain tumor using MR perfusion and spectroscopy: a meta-analysis. PLoS ONE. 2016;11:e0141438.
Aquino D, Gioppo A, Finocchiaro G, et al. MRI in glioma immunotherapy: evidence, pitfalls, and perspectives. J Immunol Res. 2017;2017:5813951.
Chiang GC, Kovanlikaya I, Choi C, et al. Magnetic resonance spectroscopy, positron emission tomography and radiogenomics-relevance to glioma. Front Neurol. 2018;9:33.
van Dijken BR, van Laar PJ, Holtman GA, et al. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol. 2017;27:4129-44.
Schlemmer HP, Bachert P, Herfarth KK, et al. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol. 2001;22:1316-24.
Plotkin M, Eisenacher J, Bruhn H, et al. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neurooncol. 2004;70:49-58.
Guo J, Yao C, Chen H, et al. The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas. Acta Neurochir. 2012;154:1361-70.
Verma N, Cowperthwaite MC, Burnett MG, et al. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol. 2013;15:515-34.
Krouwer HG, Kim TA, Rand SD, et al. Single-voxel proton MR spectroscopy of non-neoplastic brain lesions suggestive of a neoplasm. AJNR Am J Neuroradiol. 1998;19: 1695-703.
Kaminaga T, Shirai K. Radiation-induced brain metabolic changes in the acute and early delayed phase detected with quantitative proton magnetic resonance spectroscopy. J Comput Assist Tomogr. 2005;29:293-7.
Matsusue E, Fink JR, Rockhill JK, et al. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology. 2010;52:297-306.
Prat R, Galeano I, Lucas A, et al. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-d-glucosepositron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci. 2010;17:50-3.